Evidence map›Paper›PMID 36794938›Full record

ArticleAntimicrobial agents and chemotherapy2023

Correction for Underwood et al., "Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study".

Mark Underwood, Joe Horton, Keith Nangle, Judy Hopking, Kimberly Smith, Michael Aboud, Brian Wynne, Jörg Sievers, Eugene L Stewart, Ruolan Wang

Open access · greenAbstract readPublished Erratum
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Mark UnderwoodViiV Healthcare, Research Triangle Park, North Carolina, USA.ORCID 0000-0002-6803-2346
Joe HortonParexel International, Durham, North Carolina, USA.
Keith NangleParexel International, Durham, North Carolina, USA.
Judy HopkingGlaxoSmithKline, Stockley Park, United Kingdom.
Kimberly SmithViiV Healthcare, Research Triangle Park, North Carolina, USA.
Michael AboudViiV Healthcare, Brentford, United Kingdom.
Brian WynneViiV Healthcare, Research Triangle Park, North Carolina, USA.
Jörg SieversViiV Healthcare, Brentford, United Kingdom.
Eugene L StewartGlaxoSmithKline, Upper Providence, Pennsylvania, USA.
Ruolan WangViiV Healthcare, Research Triangle Park, North Carolina, USA.
PAREXEL International (United States) · USViiV Healthcare (United Kingdom) · GBGlaxoSmithKline (United Kingdom) · GBGlaxoSmithKline (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID36794938
PMCPMC10019158
OpenAlexW4321002182

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.